Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Social anxiety disorder (SAD) is more than shyness. It is a persistent, impairing condition that affects roughly 7% of the U.S. population and often resists standard treatments. SSRIs and cognitive-behavioral therapy are considered first-line, but many patients continue to experience significant symptoms even after adequate trials. In 2018, researchers at Yale University published the first randomized, placebo-controlled trial of ketamine specifically for social anxiety disorder — and the results were intriguing.
The study, led by Jerome Taylor and colleagues, was published in Neuropsychopharmacology in 2018. It used a randomized, double-blind, placebo-controlled crossover design, in which 18 adults with social anxiety disorder received both a single intravenous infusion of ketamine (0.5 mg/kg over 40 minutes) and saline placebo on separate occasions, separated by at least 28 days. This crossover approach allowed each patient to serve as their own control, increasing statistical power in a small sample.
The primary outcome was change in social anxiety symptoms as measured by the Liebowitz Social Anxiety Scale (LSAS) at multiple time points post-infusion. The study found that ketamine significantly reduced social anxiety symptoms compared to placebo. Improvement was evident within hours and, notably, some participants maintained reduced anxiety for up to 14 days after the single infusion. Effect sizes were moderate to large.
The study also assessed secondary outcomes including depression, general anxiety, and disability. Ketamine showed trends toward improvement across these measures as well, though the study was primarily powered for social anxiety. Importantly, the researchers assessed blinding integrity and found that while some participants could guess their assignment, the anxiolytic effects remained significant even after accounting for expectancy.
Social anxiety disorder has been underrepresented in the ketamine literature. Most ketamine research has focused on major depression and, to a lesser extent, PTSD and suicidal ideation. The Taylor et al. trial is significant because it demonstrates that ketamine's therapeutic potential may extend to anxiety disorders that don't primarily feature depressed mood.
From a neurobiological perspective, social anxiety involves exaggerated threat detection in the amygdala, impaired top-down regulation from the prefrontal cortex, and maladaptive learned associations between social situations and danger. The NMDA receptor system plays a well-established role in learning and memory — including fear learning. Ketamine's ability to modulate this system may help disrupt the entrenched patterns of social threat processing that maintain SAD.
For clinicians, this trial opens a conversation about ketamine as a potential option for patients with treatment-resistant social anxiety, though it is important to acknowledge the small sample size and the need for replication in larger trials. Ketamine is not FDA-approved for the treatment of social anxiety disorder.
If social anxiety has been a significant barrier in your life and standard treatments have not provided adequate relief, the Taylor et al. study suggests that ketamine may be worth exploring. The finding that a single dose could reduce social anxiety for up to two weeks is meaningful, particularly for patients who have tried multiple medications without success.
Many patients with social anxiety also experience depression, and ketamine's potential to address both conditions through a single mechanism is an appealing feature. If you're considering ketamine therapy, a physician consultation can help determine whether your clinical profile aligns with the available evidence.
The first randomized controlled trial of ketamine for social anxiety disorder found that a single IV dose significantly reduced symptoms compared to placebo, with effects lasting up to two weeks in some patients. While the sample was small and replication is needed, this study expands the range of conditions for which ketamine may offer therapeutic benefit.
Reference: Taylor JH, Landeros-Weisenberger A, Coughlin C, et al. "Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial." Neuropsychopharmacology. 2018;43(2):325-333. PMID: 29507376
If you're considering ketamine therapy, Isha Health offers physician-led at-home treatment via telemedicine in California, New York, Texas, Florida, Colorado, Arizona, Georgia, Oregon, and Washington. No in-person visit required.
